Real‐world outcomes of intensive induction approaches in core binding factor acute myeloid leukemia

• DOI: 10.1002/jha2.981
• Publication Date: 2024-07-24T08:49:00Z
• Authors: Alexandra E. Rojek; Benjamin J. McCor...; Joanna Cwykiel; Oluwatobi Odetola; Yasmin Abaza; Nhi Nai; Charles E. Foucar; Rohan K. Achar; Rory M. Shallis; Danielle Bradshaw; Meaghan Standridge; Vamsi Kota; Guru Subramanian ...; Talha Badar; Anand A. Patel
• Keywords: 0301 basic medicine; 03 medical and health sciences; intensive chemotherapy; Haematologic Malignancy ‐ Myeloid; Diseases of the blood and blood-forming organs; acute myeloid leukemia; RC633-647.5; core binding factor

Core-binding factor acute myeloid leukemia (CBF-AML) is characterized by the presence of inv(16)/t(16;16) or t(8;21) and classified as a favorable risk 2022 European LeukemiaNet (ELN) guidelines. The CD33-targeting antibody-drug conjugate, gemtuzumab ozogamicin (GO), commonly added to intensive chemotherapy (IC) in CBF-AML. We sought compare outcomes patients treated with IC without GO included 200 CBF-AML across seven academic centers. Induction treatment regimens were categorized alone, GO, KIT inhibitor (dasatinib midostaurin). Median follow-up for whole cohort was 2.5 years. Three-year overall survival (OS) 70% 3-year event-free (EFS) 51%. Patients experienced EFS 50% compared those alone who 47%, no statistically significant difference (